New hope for transplant patients: experimental drug targets stubborn GVHD
NCT ID NCT07484113
First seen Mar 22, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This early-stage study tests whether the drug sarilumab can safely help adults with chronic graft-versus-host disease (cGVHD) that has not improved with the standard treatment belumosudil. cGVHD is a complication after a stem cell transplant where the donor cells attack the patient's body. The study will enroll 10 participants and focus on safety and how the drug behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.